Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Advanced Ovarian Cancer

In brief

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Key facts

Study ID
NCT03737643
Run by
AstraZeneca
People needed
1407
Starts
2019-01-04
Expected to finish
2026-12-23
Last updated by the study team
2026-07-07

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.